ALK and lymphoma: Consistent with other reports that have shown reversal of ALK-TKI resistance in ALK-translocated lymphoma and lung cancers (33, 34), our studies provide evidence that TNO155 can restore ALK-TKI sensitivity in neuroblastoma cells and tumors harboring ALK missense mutations that have acquired resistance to lorlatinib overtime.